Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to follow up on ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

These two stocks come from completely different industries, but each could boost a long-term investor's returns.

While many top stocks have risen above the fray during periods of market recovery, others haven't followed that upward trend.

The dollar fell against a basket of currencies, after President Trump said he would nominate Stephen Miran to temporarily join the Federal Reserve's board of governors. "Miran has expressed skepticism ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Trump tweets trigger major stock swings for companies like Tesla, Boeing, Pfizer. Democrats demand an investigation.

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...